Download PDF
Semin Thromb Hemost 2009; 35(6): 574-585
DOI: 10.1055/s-0029-1240018
© Thieme Medical Publishers

New Anticoagulants in Atrial Fibrillation

Job Harenberg1
  • 1Clinical Pharmacology Mannheim, Faculty of Medicine Mannheim, Ruprecht-Karls-University Heidelberg, Mannheim, Germany
Further Information

Publication History

Publication Date:
28 September 2009 (online)

    Permissions and Reprints

ABSTRACT

Atrial fibrillation (AF) requires anticoagulation for prevention of arterial embolism, especially in the presence of defined risk factors summarized in the CHADS2 score (congestive heart disease, hypertension, age >75 years, diabetes, history of ischemic stroke or transient cerebral ischemia). Vitamin K antagonists as drugs of choice have several limitations. International normalized ratio (INR) adjustment to 2.0 to 3.0 may be difficult to maintain, and doses vary widely between patients. Inherited variations of the vitamin K epoxide reductase C1 enzyme and of the cytochrome P450 2C9 system influence the dosage as well as exogenous factors such as food and drug intake or intercurrent diseases. Increasing age and risk of falling are the main factors behind the underuse of anticoagulation in AF. Anticoagulants with a lack of all or most of these characteristics and without need of regular monitoring for dose adjustment may improve the adherence to the indication for anticoagulation. Indirect systemic and oral direct factor Xa and oral direct thrombin inhibitors are currently being developed for the prevention of embolism in patients with AF.

KEYWORDS

Atrial fibrillation - oral anticoagulants - idraparinux - oral factor Xa inhibitor - oral thrombin inhibitor

REFERENCES

  • 1 Hart R G, Pearce L A, Aguilar M I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.  Ann Intern Med. 2007;  146(12) 857-867
    CrossrefPubMedGoogle Scholar
  • 2 Go A S, Hylek E M, Henault L E et al.. Prevalence of diagnosed atrial fibrillation: national implications for management and stroke prevention: the ATRIA study.  Circulation. 1999;  100(suppl) 1-397
    PubMedGoogle Scholar
  • 3 Hylek E M, Go A S, Chang Y et al.. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.  N Engl J Med. 2003;  349(11) 1019-1026
    CrossrefPubMedGoogle Scholar
  • 4 Albers G W, Diener H C, Frison L SPORTIF Executive Steering Committee for the SPORTIF V Investigators et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial.  JAMA. 2005;  293(6) 690-698
    CrossrefPubMedGoogle Scholar
  • 5 Connolly S, Pogue J, Hart R ACTIVE Writing Group of the ACTIVE Investigators et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.  Lancet. 2006;  367(9526) 1903-1912
    CrossrefPubMedGoogle Scholar
  • 6 Boulanger L, Kim J, Friedman M, Hauch O, Foster T, Menzin J. Patterns of use of antithrombotic therapy and quality of anticoagulation among patients with non-valvular atrial fibrillation in clinical practice.  Int J Clin Pract. 2006;  60(3) 258-264
    CrossrefPubMedGoogle Scholar
  • 7 Hirsh J, O'Donnell M, Eikelboom J W. Beyond unfractionated heparin and warfarin: current and future advances.  Circulation. 2007;  116(5) 552-560
    CrossrefPubMedGoogle Scholar
  • 8 Singer D E, Albers G W, Dalen J E American College of Chest Physicians et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).  Chest. 2008;  133(6, suppl) 546S-592S
    CrossrefPubMedGoogle Scholar
  • 9 Johnson C E, Lim W K, Workman B S. People aged over 75 in atrial fibrillation on warfarin: the rate of major hemorrhage and stroke in more than 500 patient-years of follow-up.  J Am Geriatr Soc. 2005;  53(4) 655-659
    CrossrefPubMedGoogle Scholar
  • 10 van der Meer F J, Rosendaal F R, Vandenbroucke J P, Briët E. Bleeding complications in oral anticoagulant therapy. An analysis of risk factors.  Arch Intern Med. 1993;  153(13) 1557-1562
    CrossrefPubMedGoogle Scholar
  • 11 Hutten B A, Lensing A W, Kraaijenhagen R A, Prins M H. Safety of treatment with oral anticoagulants in the elderly. A systematic review.  Drugs Aging. 1999;  14(4) 303-312
    CrossrefPubMedGoogle Scholar
  • 12 Pengo V, Legnani C, Noventa F, Palareti G. ISCOAT Study Group. (Italian Study on Complications of Oral Anticoagulant Therapy) . Oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and risk of bleeding. A multicenter inception cohort study.  Thromb Haemost. 2001;  85(3) 418-422
    PubMedGoogle Scholar
  • 13 Atrial Fibrillation Investigators . Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials.  Arch Intern Med. 1994;  154(13) 1449-1457
    CrossrefPubMedGoogle Scholar
  • 14 The Stroke Prevention in Atrial Fibrillation Investigators . Bleeding during antithrombotic therapy in patients with atrial fibrillation.  Arch Intern Med. 1996;  156(4) 409-416
    CrossrefPubMedGoogle Scholar
  • 15 Fang M C, Chang Y, Hylek E M et al.. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation.  Ann Intern Med. 2004;  141(10) 745-752
    CrossrefPubMedGoogle Scholar
  • 16 Kagansky N, Knobler H, Rimon E, Ozer Z, Levy S. Safety of anticoagulation therapy in well-informed older patients.  Arch Intern Med. 2004;  164(18) 2044-2050
    CrossrefPubMedGoogle Scholar
  • 17 Schulman S, Beyth R J, Kearon C, Levine M N. American College of Chest Physicians . Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).  Chest. 2008;  133(6, suppl) 257S-298S
    CrossrefPubMedGoogle Scholar
  • 18 Bates S M, Weitz J I. The status of new anticoagulants.  Br J Haematol. 2006;  134(1) 3-19
    CrossrefPubMedGoogle Scholar
  • 19 Eikelboom J W, Weitz J I. A replacement for warfarin: the search continues.  Circulation. 2007;  116(2) 131-133
    CrossrefPubMedGoogle Scholar
  • 20 Saiah E, Soares C. Small molecule coagulation cascade inhibitors in the clinic.  Curr Top Med Chem. 2005;  5(16) 1677-1695
    CrossrefPubMedGoogle Scholar
  • 21 Bauer K A. New anticoagulants.  Curr Opin Hematol. 2008;  15(5) 509-515
    CrossrefPubMedGoogle Scholar
  • 22 Turpie A GG. Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases.  Arterioscler Thromb Vasc Biol. 2007;  27(6) 1238-1247
    CrossrefPubMedGoogle Scholar
  • 23 Ma Q, Fareed J. Idraparinux sodium. Sanofi-Aventis.  IDrugs. 2004;  7(11) 1028-1034
    PubMedGoogle Scholar
  • 24 Harenberg J, Jörg I, Vukojevic Y, Mikus G, Weiss C. Anticoagulant effects of idraparinux after termination of therapy for prevention of recurrent venous thromboembolism: observations from the van Gogh trials.  Eur J Clin Pharmacol. 2008;  64(6) 555-563
    CrossrefPubMedGoogle Scholar
  • 25 Herbert J M, Hérault J P, Bernat A et al.. Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide.  Blood. 1998;  91(11) 4197-4205
    PubMedGoogle Scholar
  • 26 Bijsterveld N R, Vink R, van Aken B E et al.. Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers.  Br J Haematol. 2004;  124(5) 653-658
    CrossrefPubMedGoogle Scholar
  • 27 PERSIST investigators . A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation.  J Thromb Haemost. 2004;  2(1) 47-53
    CrossrefPubMedGoogle Scholar
  • 28 Buller H R, Cohen A T, Davidson B van Gogh Investigators et al. Idraparinux versus standard therapy for venous thromboembolic disease.  N Engl J Med. 2007;  357(11) 1094-1104
    CrossrefPubMedGoogle Scholar
  • 29 Buller H R, Cohen A T, Davidson B van Gogh Investigators et al. Extended prophylaxis of venous thromboembolism with idraparinux.  N Engl J Med. 2007;  357(11) 1105-1112
    CrossrefPubMedGoogle Scholar
  • 30 Harenberg J, Vukojevic Y, Mikus G, Joerg I, Weiss C. Long elimination half-life of idraparinux may explain major bleeding and recurrent events of patients from the van Gogh trials.  J Thromb Haemost. 2008;  6(5) 890-892
    CrossrefPubMedGoogle Scholar
  • 31 Savi P, Herault J P, Duchaussoy P et al.. Reversible biotinylated oligosaccharides: a new approach for a better management of anticoagulant therapy.  J Thromb Haemost. 2008;  6(10) 1697-1706
    CrossrefPubMedGoogle Scholar
  • 32 Bousser M G, Bouthier J, Büller H R Amadeus Investigators et al. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial.  Lancet. 2008;  371(9609) 315-321
    CrossrefPubMedGoogle Scholar
  • 33 Buller H R, Destors J M, Gallus A S. Idrabiotaparinux, a biotinylated long-acting anticoagulant, in the treatment of deep venous thrombosis (EQUINOX Study): safety, efficacy, and reversibility by avidin.  , [abstract 32] Blood. 2008;  112 18
    PubMedGoogle Scholar
  • 34 Ansell J. Factor Xa or thrombin: is factor Xa a better target?.  J Thromb Haemost. 2007;  5(Suppl 1) 60-64
    CrossrefPubMedGoogle Scholar
  • 35 Kubitza D, Haas S. Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases.  Expert Opin Investig Drugs. 2006;  15(8) 843-855
    CrossrefPubMedGoogle Scholar
  • 36 Agnelli G, Gallus A, Goldhaber S Z ODIXa-DVT Study Investigators et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study.  Circulation. 2007;  116(2) 180-187
    CrossrefPubMedGoogle Scholar
  • 37 Buller H R, Lensing A W, Prins M H Einstein-DVT Dose-Ranging Study investigators et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study.  Blood. 2008;  112(6) 2242-2247
    CrossrefPubMedGoogle Scholar
  • 38 Pinto D J, Orwat M J, Koch S et al.. Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa.  J Med Chem. 2007;  50(22) 5339-5356
    CrossrefPubMedGoogle Scholar
  • 39 Raghavan N, Frost C E, Yu Z et al.. Apixaban metabolism and pharmacokinetics after oral administration to humans.  Drug Metab Dispos. 2009;  37(1) 74-81
    CrossrefPubMedGoogle Scholar
  • 40 Wong P C, Crain E J, Xin B et al.. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies.  J Thromb Haemost. 2008;  6(5) 820-829
    CrossrefPubMedGoogle Scholar
  • 41 Frost C, Yu Z, Moore K. Apixaban, an oral direct factor Xa inhibitor: multiple-dose safety, pharmacokinetics, and pharmacodynamics in healthy subjects.  J Thromb Haemost. 2007;  5(suppl 2) P-M-664
    PubMedGoogle Scholar
  • 42 Buller H, Deitchman D, Prins M, Segers A. Botticelli Investigators, Writing Committee . Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study.  J Thromb Haemost. 2008;  6(8) 1313-1318
    CrossrefPubMedGoogle Scholar
  • 43 Iwatsuki Y, Shigenaga T, Moritani Y et al.. Biochemical and pharmacological profiles of YM150, an oral direct factor Xa inhibitor [ASH Annual Meeting Abstracts, Abstract 911].  Blood. 2006;  108
    PubMedGoogle Scholar
  • 44 Eriksson B I, Quinlan D J, Weitz J I. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development.  Clin Pharmacokinet. 2009;  48(1) 1-22
    CrossrefPubMedGoogle Scholar
  • 45 Eriksson B I, Turpie A GG, Lassen M R ONYX study group et al. A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery.  J Thromb Haemost. 2007;  5(8) 1660-1665
    CrossrefPubMedGoogle Scholar
  • 46 Zafar M U, Vorchheimer D A, Gaztanaga J et al.. Antithrombotic effects of factor Xa inhibition with DU-176b: phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber.  Thromb Haemost. 2007;  98(4) 883-888
    PubMedGoogle Scholar
  • 47 Weitz J I, Connolly S TJ, Kunitada S. Randomized, parallel group, multicenter, multinational study evaluating safety of DU-176b compared with warfarin in subjects with non-valvular atrial fibrillation [abstract 33].  Blood. 2008; 
    PubMedGoogle Scholar
  • 48 Linkins L A, Weitz J I. Pharmacology and clinical potential of direct thrombin inhibitors.  Curr Pharm Des. 2005;  11(30) 3877-3884
    CrossrefPubMedGoogle Scholar
  • 49 Weitz J I. Factor Xa or thrombin: is thrombin a better target?.  J Thromb Haemost. 2007;  5(5, suppl 1) 65-67
    CrossrefPubMedGoogle Scholar
  • 50 Weitz J I, Büller H R. Direct thrombin inhibitors in acute coronary syndromes: present and future.  Circulation. 2002;  105(8) 1004-1011
    CrossrefPubMedGoogle Scholar
  • 51 Gustafsson D, Nyström J, Carlsson S et al.. The direct thrombin inhibitor Melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects.  Thromb Res. 2001;  101(3) 171-181
    CrossrefPubMedGoogle Scholar
  • 52 Wolzt M, Sarich T S, Eriksson U G. Pharmacokinetics and pharmacodynamics of ximelagatran.  Semin Vasc Med. 2005;  5(3) 245-253
    Article in Thieme ConnectPubMedGoogle Scholar
  • 53 Diener H C. Executive Steering Committee of the SPORTIFF III and V Investigators . Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies.  Cerebrovasc Dis. 2006;  21(4) 279-293
    CrossrefPubMedGoogle Scholar
  • 54 Boudes P F. The challenges of new drugs benefits and risks analysis: lessons from the ximelagatran FDA Cardiovascular Advisory Committee.  Contemp Clin Trials. 2006;  27(5) 432-440
    CrossrefPubMedGoogle Scholar
  • 55 Lee W M, Larrey D, Olsson R et al.. Hepatic findings in long-term clinical trials of ximelagatran.  Drug Saf. 2005;  28(4) 351-370
    CrossrefPubMedGoogle Scholar
  • 56 Gurewich V. Ximelagatran—promises and concerns.  JAMA. 2005;  293(6) 736-739
    CrossrefPubMedGoogle Scholar
  • 57 Stangier J, Rathgen K, Stähle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.  Br J Clin Pharmacol. 2007;  64(3) 292-303
    CrossrefPubMedGoogle Scholar
  • 58 Stangier J, Stähle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects.  Clin Pharmacokinet. 2008;  47(1) 47-59
    CrossrefPubMedGoogle Scholar
  • 59 Stangier J, Rathgen K, Stähle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.  Br J Clin Pharmacol. 2007;  64(3) 292-303
    CrossrefPubMedGoogle Scholar
  • 60 Ezekowitz M D, Reilly P A, Nehmiz G et al.. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study).  Am J Cardiol. 2007;  100(9) 1419-1426
    CrossrefPubMedGoogle Scholar
  • 61 Connolly S J, Ezekowitz M D, Salim Yusuf S et al.. Dabigatran versus warfarin in patients with atrial fibrillation.  N Engl J Med. 2009;  , in press
    PubMedGoogle Scholar

Job HarenbergM.D. 

Clinical Pharmacology Mannheim, Faculty of Medicine Mannheim, Ruprecht-Karls-University Heidelberg

Maybachstrasse 14, D-68169 Mannheim, Germany

Email: job.harenberg@medma.uni-heidelberg.de